Lisa Aschenbrenner
A5067120443- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Computational Drug Discovery Methods
- Antibiotic Resistance in Bacteria
- Respiratory viral infections research
- Viral Infections and Immunology Research
- Mass Spectrometry Techniques and Applications
- Analytical Chemistry and Chromatography
- Diverse Scientific Research Studies
- Plant Virus Research Studies
- Vitamin C and Antioxidants Research
- Viral gastroenteritis research and epidemiology
- Influenza Virus Research Studies
- Innovative Microfluidic and Catalytic Techniques Innovation
- Viral Infectious Diseases and Gene Expression in Insects
- Technology Assessment and Management
- Viral Infections and Vectors
- Antibiotics Pharmacokinetics and Efficacy
- Probiotics and Fermented Foods
- Metabolomics and Mass Spectrometry Studies
- Big Data and Business Intelligence
- Technology-Enhanced Education Studies
- Synthesis and biological activity
- SARS-CoV-2 detection and testing
- Endoplasmic Reticulum Stress and Disease
Pfizer (United States)
2012-2025
PRX Research
2024
Technische Universität Dresden
2023
AstraZeneca (United States)
2014
AstraZeneca (United Kingdom)
2013
Plum Island Animal Disease Center
2010
United States Department of Agriculture
2010
The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral therapeutics are an important part the healthcare response to countering ongoing threat presented COVID-19. Here, we report discovery and characterization PF-07321332, orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human activity excellent off-target selectivity vivo safety profiles. PF-07321332...
Abstract COVID-19 caused by the SARS-CoV-2 virus has become a global pandemic. 3CL protease is virally encoded protein that essential across broad spectrum of coronaviruses with no close human analogs. PF-00835231, inhibitor, exhibited potent in vitro antiviral activity against as single agent. Here we report, design and characterization phosphate prodrug PF-07304814 to enable delivery projected sustained systemic exposure PF-00835231 inhibit coronavirus family selectivity over host targets....
Despite the record-breaking discovery, development and approval of vaccines antiviral therapeutics such as Paxlovid, coronavirus disease 2019 (COVID-19) remained fourth leading cause death in world third highest United States 2022. Here, we report discovery characterization PF-07817883, a second-generation, orally bioavailable, SARS-CoV-2 main protease inhibitor with improved metabolic stability versus nirmatrelvir, component ritonavir-boosted therapy Paxlovid. We demonstrate
Abstract COVID-19 caused by the SARS-CoV-2 virus has become a global pandemic. 3CL protease is virally encoded protein that essential across broad spectrum of coronaviruses with no close human analogs. The designed phosphate prodrug PF-07304814 metabolized to PF-00835321 which potent inhibitor in vitro coronavirus family pro, selectivity over host targets. Furthermore, PF-00835231 exhibits antiviral activity against as single agent and it additive/synergistic combination remdesivir. We...
We describe a mass spectrometry (MS) analytical platform resulting from the novel integration of acoustic droplet ejection (ADE) technology, an open-port interface (OPI), and electrospray ionization (ESI)-MS that creates transformative system enabling high-speed sampling label-free analysis. The ADE technology delivers nanoliter droplets in touchless manner with high speed, precision, accuracy. Subsequent sample dilution within OPI, concert capabilities modern ESI-MS, eliminates laborious...
In early 2020, severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infections leading to COVID-19 disease reached a global level the World Health Organization (WHO) declaration of pandemic. Scientists around globe rapidly responded try and discover novel therapeutics repurpose extant drugs treat disease. This work describes preclinical discovery efforts that led invention PF-07321332 (nirmatrelvir, 14), potent orally active inhibitor SARS CoV-2 main protease (Mpro) enzyme. At outset...
The incidence of hospital-acquired infections with multidrug-resistant (MDR) Gram-negative pathogens is increasing at an alarming rate. Equally the overall lack efficacious therapeutic options for clinicians, which due primarily to acquisition and development various antibiotic resistance mechanisms that render these drugs ineffective. Among reduced permeability outer membrane, prevents many marketed antibiotics from traversing this barrier. To circumvent this, recent drug discovery efforts...
Vaccines and first-generation antiviral therapeutics have provided important protection against COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there remains a need for additional therapeutic options that provide enhanced efficacy potential viral resistance. The SARS-CoV-2 papain-like protease (PL
Multidrug-resistant Gram-negative pathogens are an emerging threat to human health, and addressing this challenge will require development of new antibacterial agents. This can be achieved through improved molecular understanding drug–target interactions combined with enhanced delivery these agents the site action. Herein we describe first application siderophore receptor-mediated drug uptake lactivicin analogues as a strategy that enables novel against clinically relevant bacteria. We...
The respiratory syncytial virus (RSV) L protein is a viral RNA-dependent RNA polymerase that contains multiple enzyme activities required for RSV replication. inhibitors described in literature are limited by their cytotoxicity or the lack of B subtype coverage. Here, we characterize new inhibitor with strong antiviral activity against both A and subtypes no detectable cytotoxicity. This compound, AZ-27, was equally active live viruses subgenomic replicons demonstrated advantages over other...
Vero cells are widely used for antiviral tests and virology research SARS-CoV-2 as well viruses from various other families. However, generally express high levels of multi-drug resistance 1 (MDR1) or Pgp protein, the efflux transporter foreign substances including many compounds, affecting activity interpretation data. To address this, a gene knockout VeroE6 cell line (VeroE6-Pgp-KO) was generated using CRISPR-CAS9 technology. These no longer expressed protein indicated by flow cytometry...
Abstract Vaccines and first-generation antiviral therapeutics have provided important protection against coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 (SARS-CoV-2). However, there remains a need for additional therapeutic options that provide enhanced efficacy potential viral resistance. The SARS-CoV-2 papain-like protease (PL pro ) is one of two essential cysteine proteases involved in replication. While inhibitors the main (M demonstrated clinical...
Abstract We describe a mass spectrometry (MS) analytical platform resulting from the novel integration of acoustic droplet ejection (ADE) technology, an open-port interface (OPI), and electrospray ionization (ESI) MS that creates transformative system enabling high-speed sampling label-free analysis. The ADE technology delivers nanoliter droplets in touchless manner with high speed, precision accuracy; subsequent sample dilution within OPI, concert capabilities modern ESI-MS, eliminates...
The worldwide outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 (SARS-CoV-2) has become an established global pandemic. Alongside vaccines, antiviral therapeutics are important part the healthcare response to counter ongoing threat presented COVID-19. Here, we report discovery and characterization PF-07321332, orally bioavailable SARS-CoV-2 main protease inhibitor with in vitro pan-human activity, excellent off-target selectivity vivo safety...

 Purpose: Despite progressing research in the field of Virtual Mobility and Internationalization at Home, recent theories technologies are challenging to implement for Higher Education Institutes (HEIs). The present paper focuses particularly on Albania, where current education system has not been able sufficiently incorporate higher programs. Study design/methodology/approach: This analyses prevalent situation within Albania’s regarding Home activities. underlying data collected...